Aerie Pharmaceuticals Inc., of Bedminster, N.J., disclosed positive top-line results from its Phase IIa study evaluating AR-13324 for the treatment of glaucoma...TransTech Pharma Inc., of High Point, N.C., said recruitment for its recently initiated Phase III trial with TTP054 in Type II diabetics is exceeding expectations with initial top-line results to be available in early 2013
Aerie Pharmaceuticals Inc., of Bedminster, N.J., disclosed positive top-line results from its Phase IIa study evaluating AR-13324 for the treatment of glaucoma...TransTech Pharma Inc., of High Point, N.C., said recruitment for its recently initiated Phase III trial with TTP054 in Type II diabetics is exceeding expectations with initial top-line results to be available in early 2013
Aerie Pharmaceuticals Inc., of Bedminster, N.J., reported top-line results from a 93-patient Phase II study testing a fixed combination of its Rho kinase inhibitor, AR-12286, with commercially available prostaglandin travoprost, for the treatment of glaucoma...Neuraltus Pharmaceuticals Inc., of Palo Alto, Calif., disclosed top-line results from the its Phase II study of NP001 in patients with amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease
Novavax Inc., of Rockville, Md., said top-line results from two Phase I trials of its A/H5N1 avian influenza vaccine candidate showed that the vaccine is safe and produces immunogenicity with and without adjuvant
Pfizer Inc., of New York, disclosed top-line Phase III data from an open-label long-term safety study of ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, noncancer pain
Summit plc, of Oxford, UK, reported top-line results from a Phase I trial of SMT C1100 in Duchenne's muscular dystrophy (DMD), showing that the study met its primary endpoints, demonstrating the formulation of the oral small molecule to be safe and well tolerated at all doses
Sophiris Bio Inc., of La Jolla, Calif., released top-line data from the 12-month follow-up of patients receiving PRX302 for the treatment of benign prostatic hyperplasia in a Phase IIb study
Both studies are on track to be completed in the second quarter of 2013, with top-line results next summer and a planned new drug application resubmission in the third quarter of 2013
Cempra Inc., of Chapel Hill, N.C., disclosed positive top-line data showing that solithromycin cleared infections in patients with uncomplicated urogenital gonorrhea
Active Biotech earned a milestone in May upon hitting the halfway mark in recruitment for the 1,200-patient study, and top-line data from the Phase III trial are expected by the end of 2013...Top-line data are expected later this quarter
Top-line data from Genzyme's second Phase III trial, ENCORE, also are expected in early 2013...Top-line data are anticipated in the second quarter of 2013
Clarus Therapeutics Inc., of Northbrook, Ill., said top-line data from the 90-day treatment phase of its ongoing Phase III study of CLR-610, an oral testosterone replacement product, demonstrated that 87 percent of the 141 men treated with CLR-610 achieved average serum T levels in the normal range (between 300 ng/dL and 1,000 ng/dL), the study's primary endpoint
Cumberland Pharmaceuticals Inc., of Nashville, Tenn., reported top-line results from a pediatric study showing that Caldolor (ibuprofen) injection was associated with a statistically significant reduction in the number of postoperative narcotic doses required in tonsillectomy patients ranging in age from 6 to 16
The company reported top-line data from the trial earlier this year. (See BioWorld Today, March 23, 2012